Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Phase 2

Recruiting

Conditions: Metastatic Colorectal Cancer
Metastatic Pancreatic Cancer
Metastatic Ovarian Cancer
Metastatic Breast Carcinoma
Metastatic Endocrine Tumors/ Neuroendocrine Tumors

Interventions: Biological: Young TIL
Drug: Aldesleukin
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Pembrolizumab (Keytruda)

First Posted Date: 2010-08-03

Last Posted Date: 2025-01-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 332

Registration Number: NCT01174121

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: dasatinib
Drug: Rituximab
Drug: fludarabine

First Posted Date: 2010-08-02

Last Posted Date: 2017-04-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 10

Registration Number: NCT01173679

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Monoblastic Leukemia
Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia
Adult Acute Monocytic Leukemia
Adult Acute Myeloid Leukemia With Maturation
Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL
Secondary Myelodysplastic Syndrome
Adult Acute Myeloid Leukemia With Minimal Differentiation

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Biological: Anti-Thymocyte Globulin
Drug: Azacitidine
Drug: Busulfan
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Other: Pharmacological Study
Drug: Tacrolimus

First Posted Date: 2010-07-23

Last Posted Date: 2022-08-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 68

Registration Number: NCT01168219

Locations: 🇺🇸
Northwell Health NCORP, Lake Success, New York, United States
🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States

and more 14 locations

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Phase 1

Withdrawn

Conditions: Hematologic Malignancy
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Acute Lymphocytic Leukemia
Chronic Myelogenous Leukemia in Blast Crisis
Chronic Myeloproliferative Disease
Anemia, Refractory, With Excess of Blasts
Small Lymphocytic Lymphoma
Marginal Zone B-cell Lymphoma
Follicular Lymphoma

Interventions: Biological: Treg cells
Biological: CD3+ Teff cells
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total body irradiation
Biological: Umbilical cord blood transplantation

First Posted Date: 2010-07-15

Last Posted Date: 2017-12-02

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Registration Number: NCT01163201

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Autologous Hematopoietic Stem Cell Transplant Recipient
Plasma Cell Leukemia
Loss of Chromosome 17p
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: bortezomib
Drug: fludarabine phosphate
Other: melphalan
Radiation: total marrow irradiation
Drug: tacrolimus
Drug: sirolimus
Procedure: peripheral blood stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2010-07-15

Last Posted Date: 2024-05-29

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 18

Registration Number: NCT01163357

Locations: 🇺🇸
City of Hope, Duarte, California, United States

Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

Phase 2

Completed

Conditions: Small Lymphocytic Lymphoma
CLL (Chronic Lymphocytic Leukemia)

Interventions: Drug: Fludarabine Phosphate
Biological: Ofatumumab
Drug: Cyclophosphamide

First Posted Date: 2010-06-16

Last Posted Date: 2023-11-28

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 32

Registration Number: NCT01145209

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.

Phase 2

Terminated

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mitoxantrone
Drug: Rituximab

First Posted Date: 2010-06-15

Last Posted Date: 2016-10-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 8

Registration Number: NCT01144403

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

Phase 2

Terminated

Conditions: Leukemia
Myelodysplastic Syndrome
Lymphoma

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil
Drug: Tacrolimus

First Posted Date: 2010-06-02

Last Posted Date: 2018-07-03

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 15

Registration Number: NCT01135329

Locations: 🇺🇸
The Sydney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Multiple Myeloma
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Thiotepa
Radiation: total body irradiation
Drug: Busulfan
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Clofarabine
Procedure: (CliniMACS) T-cell depleted PBSC Transplant

First Posted Date: 2010-05-07

Last Posted Date: 2022-08-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 422

Registration Number: NCT01119066

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Phase 2

Terminated

Conditions: Leukemia
Lymphoma
Lymphoproliferative Disorder
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms

Interventions: Biological: anti-thymocyte globulin
Biological: donor lymphocytes
Biological: filgrastim
Biological: therapeutic allogeneic lymphocytes
Drug: busulfan
Drug: fludarabine phosphate
Drug: methotrexate
Drug: mycophenolate mofetil
Drug: tacrolimus
Other: reduced-intensity transplant conditioning procedure
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2010-05-06

Last Posted Date: 2017-03-24

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 6

Registration Number: NCT01118013

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Florida Hospital Cancer Institute at Florida Hospital Orlando, Orlando, Florida, United States

and more 7 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy